TTRXTurn Therapeutics Inc.
Is it safe?
Mostly sound, with a caveat: comfortable debt (AA), but big price swings.
Net cash and profitable. A rule of thumb on leverage, not a credit rating.
Large price swings, high volatility. Worst drawdown -71% · now 25% below its 52-week high.
Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.
Can TTRX take a bad year?
Turn Therapeutics Inc. holds $3.9M more cash than debt, so a bad year is a question about profits, not about lenders.
Net cash
- Net debt / EBITDA
- net cash
Net debt / EBITDA · no net borrowings to measure against earnings
- Debt / equity
- 8.83×
Debt / equity
- Annualised volatility
- 110%
Annualised volatility · three times the market's own swing
Details›
- Total debtQ2 2026
- $6.1M
- Cash and short-term investments
- $9.9M
- Net cash
- $3.9M
- Operating profit, trailing twelve months
- −$7.0M
- Debt / equity
- 8.83×
- Annualised volatilitytwo years of daily moves
- 110%
- Worst drawdown on file
- −71%
- Below its 52-week high
- 25%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Biotechnology
The closest names by size in the same industry